TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9003857

Group type: EXPERIMENTAL
Intervention: Symmetrically growth retarded infants (low length-for-age and low weight-for-age)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Asymmetrically growth retarded infants (normal length-for-age and low weight-for-age)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Symmetric and asymmetric intrauterine growth retarded infants
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Infants born short but with normal weight
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Preterm infants with symmetric and asymmetric growth retardation
Number of subjects: 818

Group type: COMPARATOR
Intervention: Very low birth weight (< or = 1250 gm), gestational age, and broad-based day-care intervention
Number of subjects: 818
Study: 8504271

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE) (Prostin E2, 0.5 mg per tablet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE) with HSV infection
Number of subjects: 60
Study: 3027840

Group type: EXPERIMENTAL
Intervention: Regimen A: 200 mg daily for two consecutive days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regimen B: 200 mg twice a day for one day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Regimen C: 200 mg once a day for three consecutive days
Number of subjects: 60
Study: 29848422

Group type: EXPERIMENTAL
Intervention: Topical anesthesia (0.5% proparacaine hydrochloride, pledget soaked, applied 3 minutes before surgery)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Peribulbar anesthesia (3 ml of 0.5% bupivacaine, applied 3 minutes before surgery)
Number of subjects: 110
Study: 28644357

Group type: EXPERIMENTAL
Intervention: Synbiotic (scGOS/lcFOS and B. breve M-16V)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard formula (control)
Number of subjects: 30
Study: 25662557

Group type: EXPERIMENTAL
Intervention: Alvogyl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (red laser)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low level laser therapy (infrared laser)
Number of subjects: 60
Study: 23517494

Group type: EXPERIMENTAL
Intervention: Care delivered by nurses trained to respond to low complexity problems
Number of subjects: 1461

Group type: COMPARATOR
Intervention: Usual care delivered by general practitioners
Number of subjects: 1461
Study: 21611724

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sulpiride (control)
Number of subjects: 41
Study: 18572153

Group type: EXPERIMENTAL
Intervention: Huperzine A (100, 200, 300, and 400 microg doses, twice daily for a week at each dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 16534770

Group type: EXPERIMENTAL
Intervention: Presence of white matter hyperintensities at baseline
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Progression of white matter lesion volume
Number of subjects: 527
Study: 14697809

Group type: EXPERIMENTAL
Intervention: Tacrolimus and basiliximab (steroid-free)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tacrolimus and steroids (historical control)
Number of subjects: 20
Study: 10831926

Group type: EXPERIMENTAL
Intervention: Graded hormone replacement therapy (HRT) doses
Number of subjects: 153
Study: 9323077

Group type: EXPERIMENTAL
Intervention: Antiarrhythmic drug testing guided by electrophysiological study
Number of subjects: 486

Group type: COMPARATOR
Intervention: Ambulatory ECG monitoring
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Overall analysis of arrhythmic deaths/cardiac arrests during follow-up
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 486
Study: 8436464

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMX)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amoxicillin (AMX)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study: 31747930

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29868706

Group type: EXPERIMENTAL
Intervention: Intensive management
Number of subjects: 2210

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2210
Study: 26921286

Group type: EXPERIMENTAL
Intervention: Preference-based recall (text, e-mail, auto-dialer, or 2-methods)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Preference for e-mail and phone recall methods
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Recall method (receiving recalls vs not receiving recalls)
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Overall completion rates
Number of subjects: 867
Study: 24285642

Group type: EXPERIMENTAL
Intervention: Executive task evaluating fronto-striatal functioning in patients with insomnia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Successful treatment of insomnia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow-wave sleep fragmentation
Number of subjects: 0
Study: 22700830

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV-7) administered to all residents in 11 villages.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (10 villages where only children <30 months old received PCV-7).
Number of subjects: 21
Study: 20399326

Group type: EXPERIMENTAL
Intervention: Exenatide + lifestyle modification program (5 microg twice daily, increased to 10 microg after 4 weeks)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Exenatide + lifestyle modification program
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo + lifestyle modification program
Number of subjects: 194
Study: 17943589

Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia (IV‐PCA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Intramuscular analgesics (meperidine)
Number of subjects: 31
Study: 15996029

Group type: EXPERIMENTAL
Intervention: Traditional Chinese acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 60
Study: 11991427

Group type: EXPERIMENTAL
Intervention: Initial treatment with reassurance, a well-fitted brassiere, caffeine reduction, and primrose oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medications such as danazol, bromocriptine, and tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Future studies should include selective-serotonin reuptake inhibitors and primrose oil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine reduction
Number of subjects: 0
Study: 10609970

Group type: EXPERIMENTAL
Intervention: Wisconsin Smoking Withdrawal Scale
Number of subjects: 163
Study: 8609339

Group type: EXPERIMENTAL
Intervention: Coronary Angioplasty
Number of subjects: 127

Group type: COMPARATOR
Intervention: Bypass Surgery
Number of subjects: 127
Study: 1930766

Group type: EXPERIMENTAL
Intervention: Experimenter‐accompanied exercise (walking)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Social contact control condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait‐list control
Number of subjects: 30
Study: 6756707

Group type: EXPERIMENTAL
Intervention: Indomethacin (50mg q.i.d./3 days)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Bumetanide (1 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tienilic acid (250 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Captopril (100mg) in renovascular patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Captopril (25mg b.i.d./3 days) in essential hypertensive patients
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg daily/6 days)
Number of subjects: 48
Study: 31664728

Group type: EXPERIMENTAL
Intervention: Visual pedagogy and video modeling with yoga
Number of subjects: 72

Group type: COMPARATOR
Intervention: Visual pedagogy and video modeling
Number of subjects: 72
Study: 27928636

Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 46

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 46
Study: 25414430

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 1600 IU and calcium carbonate 1000 mg (D+)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Calcium carbonate alone (D-)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (D+ and D-)
Number of subjects: 150
Study: 23662292

Group type: EXPERIMENTAL
Intervention: 1200 mg gabapentin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21493417

Group type: EXPERIMENTAL
Intervention: Midazolam 50 µg/kg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 75 µg/kg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Midazolam 50 µg/kg and Midazolam 75 µg/kg
Number of subjects: 90
Study: 19458163

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients naïve to both drugs
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Combination of methotrexate (MTX) and sulfasalazine (SSZ) in patients who previously failed SSZ
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sulfasalazine (SSZ) alone in patients who previously failed SSZ
Number of subjects: 4

Group type: COMPARATOR
Intervention: Methotrexate (MTX) alone in patients naïve to both drugs
Number of subjects: 4
Study: 17928776

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (CC) 8 mg, dosage may be doubled if BP >= 140/90 mmHg, duration 8-12 weeks
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo (during 2-4 weeks run-in period)
Number of subjects: 702
Study: 15186866

Group type: EXPERIMENTAL
Intervention: Experience-based group educational programme (pharmacist-led, year-long intervention)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Experience-based group educational programme
Number of subjects: 77
Study: 11965096

Group type: EXPERIMENTAL
Intervention: Athletic students (boys)
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Athletic students (girls)
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Athletic students (boys) practicing individual 'X‐treme' sport
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Athletic students (boys) practicing collective or non‐'X‐treme' sport
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Athletic students
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Athletic students who practiced sport for seeking emotions
Number of subjects: 2926

Group type: EXPERIMENTAL
Intervention: Athletic students who did not practice sport for health benefits
Number of subjects: 2926
Study: 9624938

Group type: EXPERIMENTAL
Intervention: Room temperature alcohol swabs
Number of subjects: 53

Group type: COMPARATOR
Intervention: Pinprick
Number of subjects: 53
Study: 7530438

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) concentration method
Number of subjects: 50
Study: 3292487

Group type: EXPERIMENTAL
Intervention: Radical radiation plus microwave hyperthermia (RT + Ht)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Radical radiation (RT)
Number of subjects: 44
Study: 28939004

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000mg daily plus prednisone 10mg daily
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Prednisone 10mg daily
Number of subjects: 1088

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus prednisone
Number of subjects: 1088
Study: 28249119

Group type: EXPERIMENTAL
Intervention: 30 mL blueberry concentrate providing 387 mg anthocyanidins
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isoenergetic placebo
Number of subjects: 12
Study: 25129453

Group type: EXPERIMENTAL
Intervention: Peer adherence support (PAS)
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Treatment buddying
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Treatment buddying with PAS
Number of subjects: 294
Study: 23312695

Group type: EXPERIMENTAL
Intervention: C1 INH‐nf 1000 U (with an additional 1000 U given 1 hour later if needed)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: C1 INH‐nf 1000 U twice weekly
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: C1 INH‐nf use
Number of subjects: 46

Group type: COMPARATOR
Intervention: C1 INH‐nf
Number of subjects: 46
Study: 21200360

Group type: EXPERIMENTAL
Intervention: MenACWY-TT vaccine
Number of subjects: 784

Group type: COMPARATOR
Intervention: MenACWY-DT vaccine (Control)
Number of subjects: 784

Group type: EXPERIMENTAL
Intervention: MenACWY-TT/10 vaccine
Number of subjects: 784
Study: 18086463

Group type: EXPERIMENTAL
Intervention: PUFA supplement (eicosapentanoic acid (EPA) plus docosahexanoic acid (DHA), 2.2 mg/day in a 3:2 ratio)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Mineral oil placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Open-label PUFA administration
Number of subjects: 21
Study: 16778659

Group type: EXPERIMENTAL
Intervention: 3-blade speculum cannula for minimally invasive lumbar microdiscectomy
Number of subjects: 52
Study: 12694968

Group type: EXPERIMENTAL
Intervention: Nonclosure of the peritoneum
Number of subjects: 280

Group type: COMPARATOR
Intervention: Closure of the peritoneum
Number of subjects: 280
Study: 10673513

Group type: EXPERIMENTAL
Intervention: Doxorubicin 75 mg/m(2), intravenous bolus every 3 weeks
Number of subjects: 331

Group type: COMPARATOR
Intervention: Paclitaxel 200 mg/m(2), 3-hour infusion every 3 weeks
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Doxorubicin (second-line therapy after cross-over)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Paclitaxel (second-line therapy after cross-over)
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 331

Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 331
Study: 8926071

Group type: EXPERIMENTAL
Intervention: S. sonnei‐rEPA
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: S. flexneri‐rEPA
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: S. flexneri 2a‐rEPA
Number of subjects: 192
Study: 1671726

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 0
Study: 6548867

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy for 1 year (group A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: CMF chemotherapy for 1 year and postoperative radiation therapy (group B)
Number of subjects: 56
Study: 29504415

Group type: EXPERIMENTAL
Intervention: Naloxegol (12.5 and/or 25 mg)
Number of subjects: 2135

Group type: COMPARATOR
Intervention: Placebo/Usual care
Number of subjects: 2135

Group type: EXPERIMENTAL
Intervention: Naloxegol (all doses)
Number of subjects: 2135
Study: 27773802

Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM) 2.8g three times per day for 28 days
Number of subjects: 64
Study: 25118129

Group type: EXPERIMENTAL
Intervention: Family psychoeducation (four, two-hour biweekly multifamily psychoeducation sessions) plus treatment-as-usual for the patient (consultation by physicians)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Counseling for the family (one counseling session from a nurse) plus treatment-as-usual for the patient
Number of subjects: 0
Study: 23571150

Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-fluorouracil (HD-FU)
Number of subjects: 1601

Group type: COMPARATOR
Intervention: Standard bolus 5-fluorouracil regimen (Mayo Clinic)
Number of subjects: 1601
Study: 20967993

Group type: EXPERIMENTAL
Intervention: solifenacin (vesikar) 5 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: combined treatment
Number of subjects: 40
Study: 17581772

Group type: EXPERIMENTAL
Intervention: MedCheck intervention (electronic medication safety messages)
Number of subjects: 267
Study: 16246621

Group type: EXPERIMENTAL
Intervention: Educational intervention (viewing a series of educational videotapes and case scenarios)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 112
Study: 12821733

Group type: EXPERIMENTAL
Intervention: IV ceftriaxone 2 g daily for 30 days followed by oral doxycycline 200 mg daily for 60 days
Number of subjects: 129

Group type: COMPARATOR
Intervention: Matching IV and oral placebos
Number of subjects: 129
Study: 11035355

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 9375752

Group type: EXPERIMENTAL
Intervention: G-CSF (0.3-3.0 microg/kg/d, s.c.) and epo (60-300 U/kg/d, s.c.) for at least 10 weeks
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: G-CSF plus epo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Predictive scoring system based on pre-treatment serum epo levels and RBC transfusion need
Number of subjects: 98
Study: 8385526

Group type: EXPERIMENTAL
Intervention: Captopril (ceiling dose 100 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Lisinopril (ceiling dose 40 mg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Captopril and Lisinopril
Number of subjects: 25
Study: 2883830

Group type: EXPERIMENTAL
Intervention: Temazepam 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31415443

Group type: EXPERIMENTAL
Intervention: 4 × 4‐min high‐intensity interval training at 90% of HRMAX (4HIIT group; n = 32)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 50‐min moderate‐intensity continuous training at 70% of HRMAX (MICT group; n = 35)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 10 × 1‐min HIIT at 100% of HRMAX (1HIIT group; n = 32)
Number of subjects: 121

Group type: COMPARATOR
Intervention: No exercise control group (CONT; n = 22)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 4HIIT, MICT, and 1HIIT groups
Number of subjects: 121
Study: 30027438

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 407

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 407
Study: 27902608

Group type: EXPERIMENTAL
Intervention: Transient ulnar artery compression (UC)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 446
Study: 24788563

Group type: EXPERIMENTAL
Intervention: Cediranib alone (20 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cediranib plus dasatinib (100 mg/day)
Number of subjects: 22
Study: 23015750

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT) - 6 sessions
Number of subjects: 57

Group type: COMPARATOR
Intervention: Brief Intervention (BI) - single session
Number of subjects: 57
Study: 20837956

Group type: EXPERIMENTAL
Intervention: Rofecoxib (20 mg daily)
Number of subjects: 2434

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2434
Study: 18407016

Group type: EXPERIMENTAL
Intervention: Super Slick elastomeric rings
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional elastomeric rings
Number of subjects: 20
Study: 17876372

Group type: EXPERIMENTAL
Intervention: Sesame oil (Idhayam gingelly oil) used as the only edible oil for 45 days
Number of subjects: 50
Study: 14644892

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8206
Study: 11004026

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined cervical plexus block
Number of subjects: 40
Study: 8633488

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (H2 blocker for 2 months, then intermittent antisecretory agents for up to 1 yr)
Number of subjects: 41
Study: 1319083

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of positive lymph nodes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Degree of anaplasia
Number of subjects: 0
Study: 2859200

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 30980122

Group type: EXPERIMENTAL
Intervention: Tiopronin or D-penicillamine at 1 g/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiopronin or D-penicillamine at 2 g/day
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tiopronin or D-penicillamine at 3 g/day
Number of subjects: 10
Study: 30284393

Group type: EXPERIMENTAL
Intervention: Nepafenac (Nevanac, 1 mg/ml) for 3 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Preservative-free diclofenac (Dicloabak, 1 mg/ml) for 3 weeks
Number of subjects: 95
Study: 24731865

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) intervention for 12 months
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no CHW intervention)
Number of subjects: 300
Study: 22136324

Group type: EXPERIMENTAL
Intervention: Insulin lispro with recombinant human hyaluronidase (rHuPH20)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Regular human insulin (RHI) with recombinant human hyaluronidase (rHuPH20)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Insulin lispro alone
Number of subjects: 21
Study: 20414695

Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy (acute LDH, n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Hot-pack + laser therapy (chronic LDH, n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hot-pack + placebo laser therapy (acute LDH, n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Hot-pack + placebo laser therapy (chronic LDH, n = 20)
Number of subjects: 80
Study: 18403795

Group type: EXPERIMENTAL
Intervention: Sodium rabeprazole 20 mg orally at 2100 h the night before surgery
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 117
Study: 18511355

Group type: EXPERIMENTAL
Intervention: 1 mg/day vitamin K1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 5 mg/day vitamin K1
Number of subjects: 14
Study: 15184720

Group type: EXPERIMENTAL
Intervention: Bupropion SR (Zyban)
Number of subjects: 78
Study: 11686812

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Braun Oral‐B 3D Plaque Remover)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Manual toothbrush (Crest Complete)
Number of subjects: 48